3000-03-005/Engot-Ov44- A Randomized, Double-Blind, Phase 3 Comparison Of Platinum-Based Therapy With Tsr-042 And Niraparib Versus Standard Of Care Platinum-Based Therapy As First-Line Treatment Of Stage III Or Iv Nonmucinous Epithelial Ovarian Cancer.
Posted Date: Oct 10, 2019
- Investigator: Thomas Herzog
- Specialties: Cancer, Oncology, Ovarian Cancer
- Type of Study: Drug
The goal of this study is to compare the PFS of patients with Stage III or IV high-grade non-mucinous epithelial ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to SOC platinum-based therapy
To Be Eligible: >18 Years Of Age, Nonpregnant/Nonbreastfeeding, Confirmed High Grade Ovarian Cancer, No Active Cardiac Disease Or Cns Metastases, No Other Cancers Within 5 Years.
Ovarian Cancer, Oncology
For More Information:
Uc Cancer Institute